

CRSO Research Support Office

Children's Hospital Los Angeles

4650 Sunset Boulevard, MS-54

Los Angeles, CA 90027-6016

Phone: (323) 361-7464

FAX: (323) 361-4818

DSMC PUBLIC REPORT

DSMC Meeting Date: 5/22/19

Committee Members Present: Dr. John Quinn, Dr. David Quinn, Dr. Susan Groshen, Dr. Goldsby, and Kathy Kelly

Absent: None

Also Present: Richard Sposto, Jemily Malvar, and Narissa Antolin

Protocol #: 2012-002 Date opened to accrual: 7/28/2016

Protocol Title: T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
IND 128316

Date report period covers: 7/28/2016 to 4/26/2019

The CHLA Data Safety Monitoring Committee (DSMC) reviewed the above protocol for accrual, toxicity information and the study conduct. The following recommendations were established:

- Protocol may continue without change
- Amendment required (see below).
- Protocol closure recommended (see below).
 - Reached study endpoint
 - Toxicity concerns
 - Inadequate accrual
 - Other (specify)



John Quinn, MD
DSMC Chair